News | February 04, 2022
Lupin Q3FY22 PAT at Rs 545.52 cr.
Lupin has reported consolidated financial results for the period ended December 31, 2021
Lupin has reported consolidated financial results for the period ended December 31, 2021
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
It has signed an MoU with Plan India to expand its reach to Karnataka
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
Subscribe To Our Newsletter & Stay Updated
